All articles by
UK MHRA authorises Anastrozole for prevention of breast cancer in post-menopausal women
The approval was based on the IBIS-II study in which Anastrozole therapy resulted in fewer cases of breast cancer in women compared to the placebo group
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI as a Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation
Mirati has risen to meet one of the most challenging mutations in cancer research by developing KRAZATI, a highly selective and potent oral small-molecule inhibitor of KRAS
Viome acquires Naring Health to further its lead in personalised nutrition and longevity
Viome’s acquisition of Naring Health brings together expertise in microbiome analysis, food science, and proteomics from multiple different companies to offer more comprehensive health solutions
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
VOQUEZNA met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3 PHALCON-EE trial evaluating VOQUEZNA in comparison to a standard-of-care proton pump inhibitor
Healthpeak to merge with Physicians Realty to create $21bn healthcare operator
The combined company will start operating from Denver under the new name, Healthpeak Properties, with Healthpeak shareholders owning around 77% and Physicians Realty shareholders having the remaining 23% ownership
Phathom gets FDA nod for reformulation of Vonoprazan tablets to treat H. pylori
The approval was based on the safety and efficacy data from the phase 3 PHALCON-HP trial in which both VOQUEZNA therapy regimens showed non-inferiority to lansoprazole triple treatment
Santhera gets FDA nod for Agamree to treat Duchenne muscular dystrophy
The FDA approval was based on the findings from the phase 2b VISION-DMD trial in which Agamree met the primary endpoint Time to Stand velocity versus placebo at 24 weeks of therapy with a good safety and tolerability profile
FDA warns consumers of potential eye infection risk from certain OTC eye drops
The US health regulator has asked the consumers not to purchase and immediately stop using the products over the risk of infections that can cause partial vision loss or blindness
UK announces new £100m fund for AI advancements in healthcare and life sciences
The £100m funding, announced by the Prime Minister, will play a pivotal role in exploring how AI can contribute to finding solutions for conditions with high mortality and morbidity rates
FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema